SECTORAL ASSET MANAGEMENT INC
Long book
$120.7M
Q1 2026
Positions
77
Top-10 weight
48%
concentration
Last quarter
+8.6%
SPY +14.8%
Turnover
20%
of book per quarter
Strategy in plain words
auto-generated from filingsSECTORAL ASSET MANAGEMENT INC is a diversified fundamental manager, specialised in healthcare (93% of the long book), running a $120.7M US long book across 77 positions.
The portfolio is moderately concentrated (top 10 ≈ 48% of the book). Turnover is modest: positions are typically held for years. Current anchor positions: EVOMMUNE INC, CONTINEUM THERAPEUTICS INC-A, SHOULDER INNOVATIONS INC, ELI LILLY & CO, JOHNSON & JOHNSON.
Over the last 9 quarters its long book ran on average 1.8pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-6.7%
Q2 2024
+8.1%
Q3 2024
-5.2%
Q4 2024
-5.8%
Q1 2025
-2.8%
Q2 2025
+39.1%
Q3 2025
+22.0%
Q4 2025
-0.5%
Q1 2026
+8.6%
Sector allocation
Healthcare 92%
Financials 4%
Technology 2%
Other 2%
Long book by quarter
What does SECTORAL ASSET own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| EVMN EVOMMUNE INC | Healthcare | 589.0K | $13.5M | 11.2% | Held |
| CTNM CONTINEUM THERAPEUTICS INC-A | Healthcare | 727.6K | $9.5M | 7.9% | -9.1% |
| SI SHOULDER INNOVATIONS INC | Healthcare | 430.4K | $6.3M | 5.2% | -12.6% |
| LLY ELI LILLY & CO | Healthcare | 6.4K | $5.8M | 4.8% | -12.7% |
| JNJ JOHNSON & JOHNSON | Healthcare | 18.2K | $4.5M | 3.7% | -10.3% |
| GILD GILEAD SCIENCES INC | Healthcare | 27.5K | $4.1M | 3.4% | +53.7% |
| UNH UNITEDHEALTH GROUP INC | Financials | 15.0K | $4.0M | 3.4% | +10.0% |
| AMGN AMGEN INC | Healthcare | 9.2K | $3.5M | 2.9% | -29.5% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 7.0K | $3.5M | 2.9% | -12.5% |
| INSM INSMED INC | Healthcare | 19.7K | $3.4M | 2.8% | +75.9% |
| ABBV ABBVIE INC | Healthcare | 12.2K | $2.7M | 2.2% | -27.4% |
| ABT ABBOTT LABORATORIES | Healthcare | 25.6K | $2.6M | 2.2% | +8.9% |
| MRK MERCK & CO. INC. | Healthcare | 21.5K | $2.6M | 2.1% | +0.4% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 2.9K | $2.5M | 2.1% | -21.4% |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 5.3K | $2.4M | 2.0% | +8.2% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 34.8K | $2.2M | 1.8% | +25.9% |
| SYK STRYKER CORP | Healthcare | 5.9K | $1.9M | 1.6% | -10.3% |
| DHR DANAHER CORP | Technology | 9.6K | $1.8M | 1.5% | -9.2% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 3.5K | $1.7M | 1.4% | -10.1% |
| DXCM DEXCOM INC | Healthcare | 23.2K | $1.5M | 1.2% | -19.1% |
| IQV IQVIA HOLDINGS INC | Healthcare | 8.3K | $1.4M | 1.2% | New |
| SMMT SUMMIT THERAPEUTICS INC | Healthcare | 69.6K | $1.4M | 1.2% | -12.6% |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 17.3K | $1.4M | 1.2% | +0.5% |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 21.1K | $1.3M | 1.1% | New |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 1.7K | $1.1M | 0.9% | -0.8% |
| VERA VERA THERAPEUTICS INC | Healthcare | 25.6K | $1.1M | 0.9% | -30.6% |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 45.1K | $1.0M | 0.9% | -20.9% |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 32.5K | $1.0M | 0.8% | -28.3% |
| MDT MEDTRONIC PLC | Healthcare | 11.1K | $962K | 0.8% | New |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 74.4K | $939K | 0.8% | -11.6% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 22.1K | $902K | 0.7% | -32.3% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 31.6K | $895K | 0.7% | 0.0% |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.3K | $864K | 0.7% | -22.7% |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 11.3K | $852K | 0.7% | -23.5% |
| RAPP RAPPORT THERAPEUTICS INC | Healthcare | 25.4K | $835K | 0.7% | -34.7% |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 10.9K | $821K | 0.7% | -19.5% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 31.7K | $787K | 0.7% | -48.2% |
| ARDX ARDELYX INC | Healthcare | 122.4K | $781K | 0.6% | New |
| PFE PFIZER INC | Healthcare | 27.5K | $772K | 0.6% | +1.3% |
| BOLD BOUNDLESS BIO INC | Healthcare | 678.6K | $746K | 0.6% | Held |
| AVBP ARRIVENT BIOPHARMA INC | Healthcare | 30.0K | $720K | 0.6% | -21.5% |
| IMTX IMMATICS NV | Healthcare | 66.8K | $693K | 0.6% | +6.1% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 8.1K | $687K | 0.6% | -27.5% |
| SPRY ARS PHARMACEUTICALS INC | Healthcare | 79.2K | $677K | 0.6% | +165.6% |
| TECX TECTONIC THERAPEUTIC INC | Healthcare | 19.1K | $628K | 0.5% | -54.9% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 7.2K | $617K | 0.5% | -13.9% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 9.4K | $607K | 0.5% | -13.1% |
| KURA KURA ONCOLOGY INC | Healthcare | 71.5K | $606K | 0.5% | +32.1% |
| PRVA PRIVIA HEALTH GROUP INC | Healthcare | 27.1K | $558K | 0.5% | +4.4% |
| CYTK CYTOKINETICS INC | Healthcare | 7.3K | $545K | 0.5% | +23.9% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 77 | $120.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 9, 2026 | 74 | $124.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 82 | $162.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 94 | $151.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 84 | $128.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 86 | $149.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 90 | $169.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 97 | $246.1M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 92 | $254.4M | canonical | SEC ↗ |